FUGAZZOLA, LAURA
FUGAZZOLA, LAURA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
TP53 Alterations Associate with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer
2025 V. Cirello, C. Colombo, D. Tosi, A. Manzo, M.O. Borghi, U. Gianelli, G. Gazzano, S. Ferrero, G. Dionigi, L. Persani, L. Fugazzola
Will the autofluorescence take over inadvertent parathyroidectomy?Results from a multicentre cohort study
2025 D. Barbieri, P. Indelicato, S. DE LEO, C. Moneta, S. Coccia, G. Gazzano, L. Giordano, F. LIRA LUCE, D. Canta, L. Fugazzola, M. Bussi, G. Dionigi, M. Trevisan
Endocrinological toxicities related to immunotherapy combinations for advanced renal cell carcinoma: Practical expert-based management recommendations
2025 C. Colombo, S. De Leo, I. Campisi, E. Palesandro, F. Turco, C. Buttigliero, L. Fugazzola, M. Tucci
Utility of ultra-portable ultrasound devices for the risk-stratification of thyroid dysfunctions in an emergency setting
2025 I. Campi, L. Fugazzola
Beyond Malignancy Risk Stratification: FNAC Report Anticipates Thyroid Cancer Staging. Insights From Recent Studies
2025 M. Rotondi, M. Endo, M. Teliti, A. Crescenzi, I. Azaryan, L. Croce, R. Elisei, L. Fugazzola, E.S. Cibas, P. Trimboli, J.A. Sipos
Impact of systemic treatments for advanced thyroid cancer on the adrenal cortex
2024 C. Colombo, D. Ceruti, M. Succi, S. De Leo, M. Trevisan, C. Moneta, L. Fugazzola
Mitochondrial DNA and Ischemia Reperfusion Injury: Development of an Experimental Extra Corporeal Lung Perfusion (EVLP) Rat Model
2024 L. Rosso, I. Righi, C. Lonati, M. Battistin, M. Pinti, M. Cattaneo, V. Selleri, I. Campi, L. Fugazzola, M. Nosotti
Improved guidance is needed to optimise diagnostics and treatment of patients with thyroid cancer in Europe
2024 C. de la Fouchardière, L. Fugazzola, L.D. Locati, C.V. Alvarez, R.P. Peeters, P. Camacho, I.M. Simon, B. Jarząb, R. Netea-Maier
Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update
2024 L.A. Bischoff, I. Ganly, L. Fugazzola, E. Buczek, W.C. Faquin, B.R. Haugen, B. Mciver, C.P. Mcmullen, K. Newbold, D.J. Rocke, M.D. Russell, M. Ryder, P.M. Sadow, E. Sherman, M. Shindo, D.C. Shonka, M.C. Singer, B.C. Stack, L.J. Wirth, R.J. Wong, G.W. Randolph
Thyroid cancer and endocrine disruptive chemicals: a case–control study on per-fluoroalkyl substances and other persistent organic pollutants
2024 V. Cirello, M. Lugaresi, C. Moneta, P. Dufour, A. Manzo, E. Carbone, C. Colombo, L. Fugazzola, C. Charlier, C. Pirard
Radiofrequency ablation is an effective treatment for Bethesda III thyroid nodules without genetic alterations
2024 L. Fugazzola, M. Deandrea, S. Borgato, M. Dell'Acqua, F. Retta, A. Mormile, C. Carzaniga, G. Gazzano, G. Pogliaghi, M. Muzza, L. Persani
Characterization of EpCAM in thyroid cancer biology by three-dimensional spheroids in vitro model
2024 V. Ghiandai, E.S. Grassi, G. Gazzano, L. Fugazzola, L. Persani
dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe
2024 J.S. Rodrigues, M. Chenlo, S.B. Bravo, S. Perez-Romero, M. Suarez-Fariña, T. Sobrino, R. Sanz-Pamplona, R. González-Prieto, M.N. Blanco Freire, R. Nogueiras, M. López, L. Fugazzola, J.M. Cameselle-Teijeiro, C.V. Alvarez
Extra-nuclear TERT counteracts oxidative stress and promotes progression in papillary thyroid carcinoma
2024 M. Muzza, G. Pogliaghi, C. Colombo, E.S. Grassi, E. Carbone, S. Palazzo, F. Frattini, G. Gazzano, L. Persani, L. Fugazzola
Hypocalcemia During Lenvatinib Treatment for Advanced Thyroid Cancer: Clinical Features and Management in a Real-Life Setting
2023 S. De Leo, M. Trevisan, C. Colombo, C. Moneta, N. Giancola, L. Fugazzola
Inactivating mutations of TP53 and resistence to tyrosine-kinase inhibitors in patients affected with aggressive thyroid cancer
2023 V. Cirello, C. Colombo, A. Manzo, D. Tosi, U. Gianelli, G. Gazzano, S. Ferrero, L. Persani, L. Fugazzola
Patient-Derived in vitro models for unraveling medullary thyroid cancer microenvironment and therapy resistance
2023 E.S. Grassi, V. Ghiandai, V. Cirello, G. Gazzano, G. Dionigi, L. Persani, L. Fugazzola
Targeting the DNA damage response kinase CHK1 in TP53-mutated thyroid cancer: in vitro studies
2023 A. Manzo, V. Cirello, E.S. Grassi, C. Colombo, L. Fugazzola, L. Persani
Characterization of epcam in thyroid cancer biology by three-dimensional spheroids in vitro model
2023 V. Ghiandai, E.S. Grassi, L. Fugazzola, L. Persani
Targeting the DNA damage response kinase Chk1 in TP53-mutated aggressive thyroid cancers: in vitro studies
2023 A. Manzo, V. Cirello, E.S. Grassi, C. Colombo, L. Fugazzola, L. Persani